Back to top
more

AstraZeneca (AZN)

(Real Time Quote from BATS)

$79.15 USD

79.15
577,606

-2.66 (-3.25%)

Updated Aug 5, 2024 10:04 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

J&J's Invokana Lowers Heart Issues, Raises Amputation Risk

Johnson & Johnson (JNJ) announced data from a large CANVAS outcomes program, which demonstrated that its type II diabetes drug Invokana (canagliflozin) was successful in reducing the risks of heart attacks and strokes.

    AstraZeneca (AZN) Divests Migraine Drug Rights Beyond Japan

    AstraZeneca PLC (AZN) has inked a deal to sell the global rights of migraine treatment drug Zomig (zolmitriptan) outside Japan to Grunenthal, a German pharmaceutical company.

      Intellipharmaceutics Announces Launch of Generic Seroquel XR

      Intellipharmaceutics International Inc. (IPCI) announced the launch of a generic version of schizophrenia drug Seroquel XR by its marketing and distribution partner in the U.S, Mallinckrodt Public Limited Company

        Incyte Provides Updated Data on Cancer Combination Therapies

        Incyte along with partner Bristol-Myers Squibb announced updated data from phase I/II study, ECHO-204, evaluating epacadostat in combination with Opdivo for the treatment of squamous cell carcinoma of the head and neck and melanoma.

          Incyte Announces Data on Enzyme Inhibitor with Keytruda

          Incyte Corporation (INCY) and Merck & Co. (MRK) announced an updated data from the advanced non-small cell lung cancer patient cohort of the ongoing phase I/II ECHO-202 study.

            Big Pharma Diabetes Drugs Not So Sweet. What's in Store?

            Aales of diabetes drugs from most large pharma companies slipped in the first quarter.

              Are Nektar's (NKTR) Key Drugs Set to Drive Growth in 2017?

              On May 29, 2017, we issued an updated report on Nektar Therapeutics (NKTR).

                Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals

                After declining in 2016, share price of French pharma giant Sanofi (SNY) has picked up in 2017.

                  AstraZeneca's Bydureon Fails to Reduce Cardiovascular Risk

                  AstraZeneca plc (AZN) announced top-line results from the EXSCEL study evaluating the cardiovascular (CV) safety profile of its type II diabetes drug Bydureon.

                    The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                    The Zacks Analyst Blog Highlights: Oracle, Chubb, AstraZeneca, Estee Lauder and Aflac

                      AstraZeneca Sells Marketing Rights to Seloken in Europe

                      AstraZeneca plc (AZN) announced that it has signed an agreement with Recordati S.p.A, granting commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination to the latter in European markets.

                        AstraZeneca PLC (AZN): Strong Industry, Solid Earnings Estimate Revisions

                        AstraZeneca (AZN) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Industry Rank perspective.

                          Astrazeneca (AZN) Gets Positive CHMP Opinion for Brodalumab

                          Astrazeneca PLC (AZN) and its partner LEO Pharma received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

                            Clovis' (CLVS) PARP Inhibtor Shows Promise, Risks Remain

                            On May 19, we issued an updated research report on Boulder, CO based Clovis Oncology, Inc. (CLVS).

                              Endocyte (ECYT) Focused on Two Lead Pipeline Candidates

                              We issued an updated report on Endocyte, Inc. (ECYT) on May 17.

                                AstraZeneca Imfinzi Positive in Phase III Lung Cancer Study

                                AstraZeneca PLC (AZN) recently announced positive data from a phase III PACIFIC study evaluating its oncology candidate, Imfinzi (durvalumab).

                                  AstraZeneca (AZN) Shows Strength: Stock Moves 9.2% Higher

                                  AstraZeneca PLC (AZN) shares rose above 9% in the last trading session.

                                    What's in Store for Merck KGaA (MKGAF) in Q1 Earnings?

                                    Merck KGaA (MKGAF) is scheduled to report first-quarter 2017 earnings results on May 18.

                                      Arpita Dutt headshot

                                      Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

                                      While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

                                        Nektar Therapeutics (NKTR) Loss Wider Than Expected in Q1

                                        Nektar Therapeutics (NKTR) reported first-quarter 2017 loss of 42 cents per share, wider than the Zacks Consensus Estimate of a loss of 40 cents.

                                          Ironwood (IRWD) Q1 Loss Wider than Expected, Sales Miss

                                          Ironwood Pharmaceuticals, Inc. (IRWD) reported first-quarter 2017 adjusted loss of 33 cents per share, significantly wider than both the Zacks Consensus Estimate of a loss of 19 cents and the year-ago loss of 8 cents.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit

                                            Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.

                                              Company News for May 03, 2017

                                              Companies in the News are: COP,CVS,AZN,HLT

                                                AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates

                                                AstraZeneca PLC (AZN) reported first-quarter 2017 core earnings of 99 cents per American Depositary Share, which comfortably beat the Zacks Consensus Estimate of 38 cents.

                                                  AbbVie's (ABBV) Cancer Candidate Fails in Phase III Studies

                                                  AbbVie Inc. announced disappointing top-line results from two phase III studies evaluating veliparib in combination with chemotherapy for treatment of patients with squamous non-small cell lung cancer and triple negative breast cancer.